SIC
ICPT

Salem Investment Counselors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Salem Investment Counselors’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-143
Closed -$8K – 589
2017
Q3 		$8K Hold
143
– – ﹤0.01% 474
2017
Q2 		$17K Buy
+143
New +$16.6K ﹤0.01% 423

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Salem Investment Counselors's ICPT Position: Q4 2017 in Review

Salem Investment Counselors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2017, closing a stake of 143 shares — an estimated $8K sold.

Salem Investment Counselors first reported a position in ICPT in Q2 2017 and held it in 2 quarters. The position peaked at $17K in Q2 2017. 168 funds tracked by Wall St. Rank hold ICPT as of Q4 2017.

  • Salem Investment Counselors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Salem Investment Counselors sold 143 Intercept Pharmaceuticals, Inc. shares in Q4 2017, an estimated $8K.
  • Salem Investment Counselors first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2017 and held it in 2 quarters.
  • Salem Investment Counselors's Intercept Pharmaceuticals, Inc. position peaked at $17K in Q2 2017.
  • 168 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2017.

Based on Salem Investment Counselors's 13F filing for Q4 2017, filed 16 Feb 2018.